Wellness Clinical Research | Miami Lakes, FL

Research site

(Unclaimed)

Location

8181 NW 154 ST, STE 290, Miami Lakes, Florida, United States of America

Site insights

Top conditions

Top treatments

Mirikizumab

Dupilumab

TAK-279

PF-04965842

ABX464

TAK-101

Galcanezumab

TAK-062

Ritlecitinib

BMS-986165

Parent organization

This site is a part of Wellness Clinical Research

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 19 total trials

A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2

The purpose of this study is to learn about the safety and effects of the study medicine ritlecitinib for the possible treatment of nonsegmental viti...

Active, not recruiting

Stable Nonsegmental Vitiligo

Active Nonsegmental Vitiligo

Drug: Ritlecitinib

Drug: Placebo

A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis

The main objective of the study will be to evaluate the efficacy of rocatinlimab compared with placebo at week 24 on the patient-reported outcome (PR...

Active, not recruiting

Prurigo Nodularis

Drug: Placebo

Drug: Rocatinlimab

A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine (REBUILD-2)

The main purpose of this study is to evaluate the efficacy and safety of galcanezumab for the preventive treatment of chronic migraine in participant...

Active, not recruiting

Chronic Migraine

Drug: Placebo

Drug: Galcanezumab

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. The purpose of this study is to evaluate t...

Enrolling

Crohn's Disease

Drug: Placebo

Drug: TAK-279

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

The main aim of this study is to learn if TAK-279 reduces bowel inflammation and symptoms compared to placebo. Another aim is to compare any medical...

Enrolling

Ulcerative Colitis

Drug: TAK-279

Drug: Placebo

Locations recently updated

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis (POETYK-PsO-Ped)

The purpose of this study is to evaluate the efficacy, safety, and drug levels of Deucravacitinib (BMS-986165) in adolescent participants with modera...

Enrolling

Plaque Psoriasis

Drug: Deucravacitinib

Other: Placebo

A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

This study is designed to evaluate the long-term efficacy and safety of mirikizumab in participants with moderately to severely active ulcerative col...

Active, not recruiting

Ulcerative Colitis

Drug: Mirikizumab

ABTECT - Maintenance

This is a multicenter, randomized, placebo-controlled study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once d...

Active, not recruiting

Ulcerative Colitis

Drug: ABX464

Drug: Placebo

Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease (ENHANCE-CD)

This study has 3 treatment phases, a 12-Week Induction Phase, a 40-Week Maintenance Phase, and a 48-Week Extension Phase.The objective is to evaluate...

Enrolling

Moderately to Severely Active Crohn Disease

Drug: Obefazimod

Other: Placebo